New Trial Results: “SPaL” Regimen Continues to Show Promise as a Shorter, Simpler, People-Centered TB Treatment

Promising new Phase 2 results from the NC-009 trial highlight the potential of the SPaL regimen to deliver shorter, simpler, and more people-centered TB treatment. This emerging therapy could build on the success of BPaL/M and bring transformative benefits to both drug-resistant and drug-sensitive TB care.